Prognostic Value of Serum Epstein-Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma
PURPOSE: This study assessed the correlation between Epstein-Barr virus (EBV) biomarkers and the eighth American Joint Committee on Cancer staging system and the prognostic values of IgG antibodies against replication and transcription activator (Rta-IgG), IgA antibodies against Epstein-Barr nuclear antigen 1, and BamH1 Z transactivator (Zta-IgA) in locoregionally advanced nasopharyngeal carcinoma (NPC) patients.
MATERIALS AND METHODS: Serum EBV antibody levels were measured by enzyme-linked immunosorbent assay in 435 newly diagnosed stage III-IVA NPC patients administered intensity-modulated radiation therapy±chemotherapy. The primary endpoint was progression-free survival (PFS).
RESULTS: Rta-IgG and Zta-IgA levels were positively correlated with the N category and clinical stage. Patients with high Rta-IgG levels (> 29.07 U/mL) showed a significantly inferior prognosis as indicated by PFS (77% vs. 89.8%, p=0.004), distant metastasis-free survival (DMFS) (88.3% vs. 95.8%, p=0.021), and local recurrence-free survival (LRFS) (91.2% vs. 98.3%, p=0.009). High Rta-IgG levels were also significantly associated with inferior PFS and LRFS in multivariable analyses. In the low-level EBV DNA group (≤ 1,500 copies/mL), patients with high Rta-IgG levels had significantly inferior PFS and DMFS (both p < 0.05). However, in the high-level EBV DNA group, Rta-IgG levels were not significantly associated with PFS, DMFS, and LRFS. In the advanced T category (T3-4) subgroup, high Rta-IgG levels were also significantly associated with inferior PFS, DMFS, and LRFS (both p < 0.05).
CONCLUSION: Rta-IgG and Zta-IgA levels were strongly correlated with the TNM classification. Rta-IgG level was a negative prognostic factor in locoregionally advanced NPC patients, especially those with advanced T category or low EBV DNA level.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
---|---|
Enthalten in: |
Cancer research and treatment - 53(2021), 4 vom: 20. Okt., Seite 991-1003 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Zhang, Wan-Ru [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 07.02.2022 Date Revised 27.04.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.4143/crt.2020.1298 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM320561674 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM320561674 | ||
003 | DE-627 | ||
005 | 20231225173839.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.4143/crt.2020.1298 |2 doi | |
028 | 5 | 2 | |a pubmed24n1068.xml |
035 | |a (DE-627)NLM320561674 | ||
035 | |a (NLM)33494127 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Zhang, Wan-Ru |e verfasserin |4 aut | |
245 | 1 | 0 | |a Prognostic Value of Serum Epstein-Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 07.02.2022 | ||
500 | |a Date Revised 27.04.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a PURPOSE: This study assessed the correlation between Epstein-Barr virus (EBV) biomarkers and the eighth American Joint Committee on Cancer staging system and the prognostic values of IgG antibodies against replication and transcription activator (Rta-IgG), IgA antibodies against Epstein-Barr nuclear antigen 1, and BamH1 Z transactivator (Zta-IgA) in locoregionally advanced nasopharyngeal carcinoma (NPC) patients | ||
520 | |a MATERIALS AND METHODS: Serum EBV antibody levels were measured by enzyme-linked immunosorbent assay in 435 newly diagnosed stage III-IVA NPC patients administered intensity-modulated radiation therapy±chemotherapy. The primary endpoint was progression-free survival (PFS) | ||
520 | |a RESULTS: Rta-IgG and Zta-IgA levels were positively correlated with the N category and clinical stage. Patients with high Rta-IgG levels (> 29.07 U/mL) showed a significantly inferior prognosis as indicated by PFS (77% vs. 89.8%, p=0.004), distant metastasis-free survival (DMFS) (88.3% vs. 95.8%, p=0.021), and local recurrence-free survival (LRFS) (91.2% vs. 98.3%, p=0.009). High Rta-IgG levels were also significantly associated with inferior PFS and LRFS in multivariable analyses. In the low-level EBV DNA group (≤ 1,500 copies/mL), patients with high Rta-IgG levels had significantly inferior PFS and DMFS (both p < 0.05). However, in the high-level EBV DNA group, Rta-IgG levels were not significantly associated with PFS, DMFS, and LRFS. In the advanced T category (T3-4) subgroup, high Rta-IgG levels were also significantly associated with inferior PFS, DMFS, and LRFS (both p < 0.05) | ||
520 | |a CONCLUSION: Rta-IgG and Zta-IgA levels were strongly correlated with the TNM classification. Rta-IgG level was a negative prognostic factor in locoregionally advanced NPC patients, especially those with advanced T category or low EBV DNA level | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Epstein–Barr virus antibodies | |
650 | 4 | |a Nasopharyngeal carcinoma | |
650 | 4 | |a Prognosis | |
650 | 4 | |a TNM classification | |
650 | 7 | |a Antibodies, Viral |2 NLM | |
650 | 7 | |a Biomarkers, Tumor |2 NLM | |
650 | 7 | |a Epstein-Barr Virus Nuclear Antigens |2 NLM | |
650 | 7 | |a Immunoglobulin A |2 NLM | |
650 | 7 | |a Immunoglobulin G |2 NLM | |
650 | 7 | |a EBV-encoded nuclear antigen 1 |2 NLM | |
650 | 7 | |a O5GA75RST7 |2 NLM | |
700 | 1 | |a Du, Yu-Yun |e verfasserin |4 aut | |
700 | 1 | |a Guo, Chun-Yan |e verfasserin |4 aut | |
700 | 1 | |a Zhou, Han-Xing |e verfasserin |4 aut | |
700 | 1 | |a Lin, Jie-Yi |e verfasserin |4 aut | |
700 | 1 | |a Meng, Xiao-Han |e verfasserin |4 aut | |
700 | 1 | |a Mo, Hao-Yuan |e verfasserin |4 aut | |
700 | 1 | |a Luo, Dong-Hua |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cancer research and treatment |d 2001 |g 53(2021), 4 vom: 20. Okt., Seite 991-1003 |w (DE-627)NLM190743158 |x 2005-9256 |7 nnns |
773 | 1 | 8 | |g volume:53 |g year:2021 |g number:4 |g day:20 |g month:10 |g pages:991-1003 |
856 | 4 | 0 | |u http://dx.doi.org/10.4143/crt.2020.1298 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 53 |j 2021 |e 4 |b 20 |c 10 |h 991-1003 |